EZH2 and small cell lung carcinoma: EZH2 expression is higher in SCLC than in any tumor type included in the Cancer Genome Atlas (34), and preclinical analysis showed that an EZH2 inhibitor augmented chemotherapeutic efficacy and could prevent emergence of acquired chemotherapy resistance in multiple in vivo SCLC patient-derived xenograft models (35).